XP Chemistries AB
STO:XPC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
X
|
XP Chemistries AB
STO:XPC
|
SE |
|
Aptevo Therapeutics Inc
NASDAQ:APVO
|
US |
|
S
|
Shanxi Antai Group Co Ltd
SSE:600408
|
CN |
|
Biome Technologies PLC
LSE:BIOM
|
UK |
|
FiEE Inc
NASDAQ:FIEE
|
US |
|
C
|
Cabbacis Inc
OTC:CABI
|
US |
Balance Sheet
Balance Sheet Decomposition
XP Chemistries AB
XP Chemistries AB
Balance Sheet
XP Chemistries AB
| Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & Cash Equivalents |
21
|
15
|
8
|
2
|
15
|
|
| Cash Equivalents |
21
|
15
|
8
|
2
|
15
|
|
| Total Receivables |
1
|
0
|
1
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
1
|
0
|
1
|
0
|
0
|
|
| Inventory |
1
|
1
|
2
|
2
|
2
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
24
|
17
|
10
|
5
|
18
|
|
| PP&E Net |
3
|
3
|
2
|
2
|
1
|
|
| Intangible Assets |
3
|
4
|
6
|
6
|
6
|
|
| Goodwill |
3
|
2
|
2
|
1
|
0
|
|
| Other Long-Term Assets |
2
|
4
|
7
|
9
|
13
|
|
| Other Assets |
3
|
2
|
2
|
1
|
0
|
|
| Total Assets |
34
N/A
|
31
-11%
|
27
-11%
|
23
-16%
|
38
+68%
|
|
| Liabilities | ||||||
| Accounts Payable |
2
|
1
|
1
|
0
|
0
|
|
| Accrued Liabilities |
1
|
1
|
1
|
1
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
3
|
2
|
2
|
1
|
1
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
3
N/A
|
2
-49%
|
2
-5%
|
1
-23%
|
1
-2%
|
|
| Equity | ||||||
| Common Stock |
1
|
1
|
3
|
5
|
10
|
|
| Retained Earnings |
3
|
11
|
19
|
26
|
34
|
|
| Additional Paid In Capital |
33
|
39
|
41
|
42
|
61
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
31
N/A
|
29
-7%
|
26
-12%
|
22
-16%
|
37
+71%
|
|
| Total Liabilities & Equity |
34
N/A
|
31
-11%
|
27
-11%
|
23
-16%
|
38
+68%
|
|
| Shares Outstanding | ||||||
| Common Shares Outstanding |
29
|
37
|
96
|
149
|
314
|
|